Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

Diabetes Care

Volumn 24, Issue 4, 2001, Pages 720-725

  Zander, Mette ^a,b   Taskiran, Mustafa ^a   Toft Nielsen, Mai Britt ^a   Madsbad, Sten ^a   Holst, Jens Juul ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN;

ADULT; APPETITE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTERMETHOD COMPARISON; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034827252     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.4.720     Document Type: Article

References (32)

1. Pharmacologic therapy for type 2 diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
4. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
5. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
6. Metformin: A review of its metabolic effects
7. A risk-benefit assessment of metformin in type 2 diabetes mellitus
8. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
9. Metformin
10. Sulfonylurea receptors and mechanism of sulfonylurea action
11. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
12. Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells
13. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1) (7-36)amide in type 2 (non-insulin-dependent) diabetic patients
14. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
15. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells
16. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats
17. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metagonlite in vivo
18. 2-terminus in type 2 diabetic patients and healthy subjects
19. Additive glucose-lowering effects of GLP-1 and metformin in type 2 diabetes
20. Proposal for standardizing direct-reading biosensors for blood glucose
21. Proglucagon products in plasma from non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginine
22. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans
23. Potential therapeutic levels of glucagon-like peptide- 1 achieved in humans by a buccal tablet
24. Efficacy of metformin in type II diabetes: Results of a doubleblind, placebo-controlled, dose-response trial
25. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
26. Glucagon-like peptide- 1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
27. Effects of metformin on baseline and oral glucose-induced glucagon-like peptide-1 (GLP-1) in obese non-diabetic subjects
28. Determinant of the effectiveness of GLP-1 in type 2 diabetes
29. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
30. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type 1 diabetic patients
31. Repeated intracerebro-ventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat
32. Pharmacokinetic, insulinotropic and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers: Dose-response-relationships